Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Payables (2017 - 2025)

Historic Payables for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $1.7 million.

  • Vistagen Therapeutics' Payables rose 6169.39% to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 million, marking a year-over-year increase of 6169.39%. This contributed to the annual value of $653000.0 for FY2025, which is 5778.93% down from last year.
  • Per Vistagen Therapeutics' latest filing, its Payables stood at $1.7 million for Q4 2025, which was up 6169.39% from $2.5 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Payables peaked at $6.5 million during Q2 2022, and registered a low of $653000.0 during Q1 2025.
  • Over the past 5 years, Vistagen Therapeutics' median Payables value was $1.8 million (recorded in 2021), while the average stood at $2.1 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 42178.42% in 2021, then plummeted by 6461.3% in 2023.
  • Vistagen Therapeutics' Payables (Quarter) stood at $1.9 million in 2021, then grew by 3.55% to $2.0 million in 2022, then dropped by 13.92% to $1.7 million in 2023, then crashed by 40.18% to $1.0 million in 2024, then skyrocketed by 61.69% to $1.7 million in 2025.
  • Its Payables stands at $1.7 million for Q4 2025, versus $2.5 million for Q3 2025 and $1.4 million for Q2 2025.